Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Global Optic Neuropathy Therapeutics Pipeline Review 2016: 7 Companies & 14 Molecules - Research and Markets

Research and Markets
Posted on: 30 Sep 16

Research and Markets has announced the addition of the "Optic Neuropathy - Pipeline Review, H2 2016" report to their offering.

Optic Neuropathy pipeline therapeutics constitutes close to 14 molecules. Out of which approximately 8 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Optic Neuropathy - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Optic Neuropathy Overview
  3. Therapeutics Development
  4. Pipeline Products for Optic Neuropathy - Overview
  5. Pipeline Products for Optic Neuropathy - Comparative Analysis
  6. Optic Neuropathy - Therapeutics under Development by Companies
  7. Optic Neuropathy - Therapeutics under Investigation by Universities/Institutes
  8. Optic Neuropathy Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Optic Neuropathy - Products under Development by Companies
  13. Optic Neuropathy - Products under Investigation by Universities/Institutes
  14. Optic Neuropathy - Companies Involved in Therapeutics Development
  • Amgen Inc.
  • BioAxone BioSciences, Inc.
  • Inotek Pharmaceuticals Corporation
  • Ironwood Pharmaceuticals, Inc.
  • PharmatrophiX, Inc.
  • Quark Pharmaceuticals, Inc.
  • Regenera Pharma Ltd.

For more information about this report visit

View source version on

Business Wire

Last updated on: 30/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.